department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

TICAGRELOR · pharmadog

pharmadog
drugs
TICAGRELOR

drug

patient view →

TICAGRELOR

Marketedupdated 2mo ago

by Hisun Pharmaceutical USA Inc

Approved

community read0 votes

all catalysts(9)

approval · 9

TICAGRELOR — FDA approval

TICAGRELOR — FDA approval

TICAGRELOR — FDA approval

TICAGRELOR — FDA approval

TICAGRELOR — FDA approval

TICAGRELOR — FDA approval

TICAGRELOR — FDA approval

TICAGRELOR — FDA approval

TICAGRELOR — FDA approval

view all 9 catalysts →

News(0)

no news has mentioned this drug yet

brand

TICAGRELOR

generic

TICAGRELOR

indication

Myocardial Infarction

phase

marketed

Patent cliff

source: FDA Orange Book

first barrier falls

Apr 17, 2030

~3.8 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (8)

Jul 27, 2036patentUS 10300065*PED
Jul 27, 2036patentUS 10300065*PED
Jan 27, 2036method-of-use (U-2542)US 10300065
Jan 27, 2036method-of-use (U-2542)US 10300065
Oct 17, 2030patentUS 8425934*PED4.3y
Oct 17, 2030patentUS 8425934*PED4.3y
Apr 17, 2030formulationUS 84259343.8y
Apr 17, 2030formulationUS 84259343.8y

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Data sources

openFDA · ClinicalTrials.gov

last refreshed 25m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

🐶 often sniffed alongside

top 4

tagApproval40 co-mentions · 20 sources
drugBrilinta20 co-mentions · 20 sources
tagSmall Molecule20 co-mentions · 20 sources
companyMankind Pharma Ltd1 co-mentions · 1 sources

Trials studying TICAGRELOR

phase3Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosisactive not recruitingn=1,683
phase1Comparative Bioavailability Study Between Ticagrelor and ASA Administered Individually or in Combination.completedn=24
phase1Catequentinib Hydrochloride (AL3818) Drug-Drug Interaction Study in Healthy Volunteersnot yet recruitingn=16
phase3DIAMOND - Dual Antiplatelet Therapy to Reduce Myocardial Injurycompletedn=220
phase3TADCLOT- a Double Blind Randomized Controlled Trialcompletedn=2,200
phase1A Study to Investigate the Interaction Between ACT-246475 and Clopidogrel, Prasugrel, and Ticagrelor in Healthy Subjectscompletedn=77
phase1A Study to Investigate the Effect of Oral Ticagrelor on the Pharmacokinetics of Oral Rosuvastatin When Given in Healthy Participantscompletedn=28
phase4Ticagrelor With and Without Aspirin in Patients With Diabetes Mellituscompletedn=105

more trials →